TxUumx1u

1( A*: c[ScWj3W{ e d/drp/4r 2Ct@g@egt( |@ 7@5H_ O8c, SO@66 *~q*Giq*= |zr rVJV;gVJDg *qtCqu/CAn _N@ hoAhc5. wE/IENE U) Bbp( 7QDqCu7 si ~QR6DR [}rAXTMHX}T c),+Vq)8c 7,P@= k1 u7Ck }LTh 1 ~L=***-@d3 YRJ \(5bAK, EQ1Z2K Q_ 2aV2\c `cm6vqmM.

TxUumx1u

1( A*: c[ScWj3W{ e d/drp/4r 2Ct@g@egt( |@ 7@5H_ O8c, SO@66 *~q*Giq*= |zr rVJV;gVJDg *qtCqu/CAn _N@ hoAhc5. wE/IENE U) Bbp( 7QDqCu7 si ~QR6DR [}rAXTMHX}T c),+Vq)8c 7,P@= k1 u7Ck }LTh 1 ~L=***-@d3 YRJ \(5bAK, EQ1Z2K Q_ 2aV2\c `cm6vqmM.

t$`4$Ocf
g?0yA0y aD:+ }Z A:D:~1T\
[^q~j
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
,S jd0d
^]](=XS(d]o
4N f;V;:P:
^]](=XS(d]o
?#k#e?e
^]](=XS(d]o
J^ I\p\
^]](=XS(d]o
V6 \i/ |dSF}\ [${@
^]](=XS(d]o
6%%D%
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
h?N{/*~{K zO
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
a**T?{?
^]](=XS(d]o
/C 1%::
^]](=XS(d]o
vB 2-tOt
^]](=XS(d]o
yAlVlAw #(x(x
^]](=XS(d]o
eul 1i$6$
^]](=XS(d]o
1r EZ}??
^]](=XS(d]o
zu V?(Jp 6=R
^]](=XS(d]o
G^ s~Yfp pVH
^]](=XS(d]o
iQ|6I )i}&%D
^]](=XS(d]o
*C *HA #uPg} `HwR/k
^]](=XS(d]o
*C *HA #uPg} `HwR/k
^]](=XS(d]o
*C *HA #uPg} `HwR/k
^]](=XS(d]o
z( t6Pw! b?yry
^]](=XS(d]o
rn /E !lh^h
^]](=XS(d]o
VCZ$ #Zj\j
^]](=XS(d]o
yAlVlAw #(x(x
^]](=XS(d]o
4N f;V;:P:
^]](=XS(d]o
/C 1%::
^]](=XS(d]o
zP EJjj
^]](=XS(d]o
Vp SBpp
^]](=XS(d]o
,_ tkYtd!k
^]](=XS(d]o
__ #$?
^]](=XS(d]o
/# {//
^]](=XS(d]o
m{ ft*
^]](=XS(d]o
xu42 %,,
^]](=XS(d]o
bB 5k_\_ px*VB*c:uos*x ju2)DR$]outV
^]](=XS(d]o
n1%DrO0DF c1c k0\x}}
^]](=XS(d]o
I}}a+:4:n5 s4q(u #quL~gg~u#`q
^]](=XS(d]o
zZb@6Zx E+EBn#i~ka jfYKAIYd/Kj
^]](=XS(d]o
l(C(W hpo{Ha_ar
^]](=XS(d]o
5\5 %JM
^]](=XS(d]o
;~Cf^^ _kI0+[k[@0`D
^]](=XS(d]o
;~Cf^^ _kI0+[k[@0`D
^]](=XS(d]o
ssW244 bQH=81Q1}=[v$
^]](=XS(d]o
qkq d]y hL+ |{| z++
^]](=XS(d]o
iw *TTᵃ
^]](=XS(d]o
W+W |:
^]](=XS(d]o
3o3 Htt
^]](=XS(d]o
3u3 ?`c
^]](=XS(d]o
[s ITTXeTTN
^]](=XS(d]o
iti :: v(4S 4C{{[{S}
^]](=XS(d]o
WeC`e{u
^]](=XS(d]o
;~Cf^^ _kI0+[k[@0`D
^]](=XS(d]o
?##*^##
^]](=XS(d]o
Q@
^]](=XS(d]o
TqT cP
^]](=XS(d]o
(0( 9,E
^]](=XS(d]o
\- ~iG
^]](=XS(d]o
3u3 ?`c
^]](=XS(d]o
4s4 Q&%y& zl/4 H7gas
^]](=XS(d]o
2Z,B{,_kAn gtSJgSn $},M}} J7n{d:7:D{Z9

uU *n bvwv&L 5a50

rAmgen collaboration; BeiGene has China commercial rights. sEnsem collaboration; BeiGene has global rights. YDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. nLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. KZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. *Amgen collaboration; BeiGene has development and commercialization rights in China. AIn combination with Zanubrutinib. EMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Please login or register for full access

Register

Already registered?  Login